GeneDx
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as ...
Latest News
5 days ago · businesswire.com
GeneDx to Participate in Upcoming Investor ConferencesGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx to Participate in Upcoming Investor Conferences.
6 days ago · fool.com
Why GeneDx Holdings Stock Just Dropped 16.6%GeneDx lowered its 2026 exome and genome volume growth target to at least 28% after third-quarter testing volume fell short of expectations. Sales rose 5% to $123.1 million, in line with estimates, but the 32,134 exome and genome results were up 25% against the 29.2% or more the company had promised.
7 days ago · seekingalpha.com
GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call TranscriptGeneDx Holdings Corp. ( WGS ) Q3 2026 Earnings Call November 9, 2026 4:30 PM EST Company Participants Sabrina Dunbar - Director of Investor Relations & Communications Katherine Stueland - CEO & Director Mark Gardner - President Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen, Research Division David Westenberg - Piper Sandler & Co., Research Division Tycho Peterson - Jefferies LLC, Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Keith Hinton - Prime Executions, Inc., Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2026 Earnings Conference Call.
7 days ago · seekingalpha.com
GeneDx: Q3 Earnings Indicate Transition To Sustained ProfitabilityGeneDx Holdings is transitioning to sustained profitability, with strong revenue growth expected through 2027. WGS beat revenue estimates for Q3 but fell short on EPS estimates. Key strategies include optimizing reimbursement rates, operational efficiencies, and leveraging AI to enhance billing and payment reliability.
7 days ago · marketbeat.com
GeneDx Q3 Earnings Call HighlightsGeneDx NASDAQ: WGS reported third-quarter revenue of $123.1 million and raised its full-year profitability outlook, even as new documentation requirements led the genetic testing company to lower its expectations for test volume growth.
7 days ago · zacks.com
GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue EstimatesGeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.49 per share a year ago.
12 days ago · businesswire.com
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic TestingGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.
20 days ago · prnewswire.com
Did GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
24 days ago · businesswire.com
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference ca.
28 days ago · businesswire.com
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights five areas: Scaling genomic interpretation with AI and machine learning: A GeneDx.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove WGS